Skip to main content

Table 3 The association of antiplatelet drugs with VAF for AVG

From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

Author Design N (Control) Exposure Timing Outcome (duration) VAF development Number of Bleeding events (Control)
Harter et al [66] Placebo-controlled 44 (NA) Aspirin
160 mg/day
NA
AVG thrombosis (5 months) Lower risk
(32% vs. 72%, P < 0.01)
NA
Sreedhara et al [65] Placebo-controlled 53 (24) Dipyridamole
225 mg 3× /day
Pre
AVG thrombosis (18 months) Lower risk
(42% vs. 80%, RR 0.35, P = 0.02)
2
(5)
NS
Kaufman et al [64] Placebo-controlled 200 (96) Clopidogrel
75 mg/day
+ Aspirin
325 mg/day
Post
AVG thrombosis (stopped by bleeding risk) Equivalent risk
(HR 0.81, 95% CI 0.47–1.40, P = 0.45)
38
(67)
P = 0.006
Trimarchi et al [63] Placebo-controlled 19 (8) Clopidogrel
75 mg/day
Post
Time to AVG thrombosis Lower risk
(350 vs. 86 days, P < 0.001)
None
Dixon et al [61] Placebo-controlled 649 (328) Dipyridamole 400 mg 2× /day
+ Aspirin
50 mg 2× /day
Post
Primary patency rates of AVG (4.5 years) Lower risk
(HR 0.82, 95% CI 0.68–0.98, P = 0.03)
40
(37)
NS
  1. VAF vascular access failure, AVG arteriovenous graft, RR relative risk, HR hazard ratio, CI confidential interval, NS not significant, NA not available, Pre pre-operative period, Post post-operative period